Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016061 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL2012153 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL2009498 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL14152352 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL2010947 | 1.00 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL2010262 | 0.98 | TSHR (0.52) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2013628 | 0.92 | TSHR (0.54) | TSHRLMNAALDH1A1KMT2AESR2 | |
| SCHEMBL2011016 | 0.84 | TSHR (0.50) | TSHRLMNAALDH1A1KMT2ACA12 | |
| SCHEMBL2014494 | 0.82 | DGKA (0.47) | TSHRALDH1A1KMT2A | |
| SCHEMBL2012721 | 0.82 | DGKA (0.47) | TSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100014-B1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | NICOX SA (FR) | 2024-01-03 | — | — | EP | claimed |
| WO-2023161314-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | NICOX SA (FR) | 2023-08-31 | — | — | WO | claimed |
| US-20250320182-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | NICOX SA (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4551553-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | Nicox S.A. (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119522211-A | Industrial process and high purity product for the preparation of (1S, 2E) -3- [ (1R, 2R,3S, 5R) -2- [ (2Z) -7- (ethylamino) -7-oxo-2-hepten-1-yl ] -3, 5-dihydroxycyclopentyl ] -1- (2-phenylethyl) -2-propen-1-yl 6- (nitrooxy) -hexanoate | 尼科斯股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4440549-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Nicox SA (FR) | 2024-10-09 | — | — | EP | disclosed |
| EP-4303211-B1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6(NITROOXY)-,(1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYL ETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | NICOX SA (FR) | 2024-08-21 | — | — | EP | disclosed |
| EP-4410294-A2 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6(NITROOXY)-,(1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYL ETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | Nicox S.A. (FR) | 2024-08-07 | — | — | EP | disclosed |
| US-20240018096-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | NICOX S.A. (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2024008844-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | NICOX S.A. (FR) | 2024-01-11 | — | — | WO | disclosed |
| EP-4303211-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6(NITROOXY)-,(1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYL ETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | Nicox S.A. (FR) | 2024-01-10 | — | — | EP | disclosed |
| EP-4100014-A1 | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | Nicox S.A. (FR) | 2022-12-14 | — | — | EP | disclosed |
| US-9365489-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2016-06-14 | — | — | US | disclosed |
| US-8784871-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2014-07-22 | — | — | US | disclosed |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2014-05-15 | — | — | US | disclosed |
| EP-2509435-B1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS BV (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2012-12-13 | — | — | US | disclosed |
| EP-2509435-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP Assets B.V. (NL) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070133-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2011-06-16 | — | — | WO | disclosed |
| WO-2009136281-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320182-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | CYP2A13, HPD, CYP51A1 | TSHR 790/4885LMNA 4154/4885ALDH1A1 503/4885 |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | TSHR 630/4885LMNA 901/4885ALDH1A1 2126/4885 |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | TSHR 630/4885LMNA 901/4885ALDH1A1 2126/4885 |
| US-20240018096-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT | CYP2A13, HPD, CYP51A1 | TSHR 790/4885LMNA 4154/4885ALDH1A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.